Cytek grew revenue and losses in the first quarter.
/PRNewswire/ -- Cytek Biosciences Inc (NASD:CTKB) will replace Cardiovascular Systems Inc. (NASD:CSII) in the S&P SmallCap 600 effective prior to the opening...
Second quarter revenue grew 32% compared to prior year...
FREMONT, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced the company...
FREMONT, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will...
/PRNewswire/ -- Recently, Yahui Zhou, the founding partner of Kunlun Capital, won the 36kr 2022 " China 100 Best Investors Voted by Entrepreneurs " award and...
FREMONT, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) announced today that it will...
Company Moves to Make Total Cell Analysis Solutions Available for Clinical Applications in the European Market...
First quarter revenue grew 44% compared to prior year...
2021 Revenue Increased 38% Compared to Prior Year FREMONT, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or...